BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) contiguous announced that aggregate abstracts connected the company’s portfolio of cystic fibrosis (CF) medicines volition beryllium presented successful posters and oral presentations astatine this year’s North American Cystic Fibrosis Conference (NACFC), including studies demonstrating the objective benefits and semipermanent information of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor).
Vertex volition contiguous caller semipermanent information and efficacy information connected TRIKAFTA from an open-label 192-week hold survey successful radical 12 years and older with CF and astatine slightest 1 F508del allele. Based connected an interim investigation done Week 144 of the 192-week study, radical receiving TRIKAFTA showed maintained improvements successful lung function, respiratory symptoms and cystic fibrosis transmembrane conductance regulator (CFTR) function. TRIKAFTA besides continues to beryllium mostly good tolerated (Poster #170 and Oral Workshop: W21.2). These information volition besides beryllium discussed during the 2nd plenary connected November 4, 2022, astatine NACFC.
“These semipermanent information astatine 144 weeks show singular wellness effects successful the longest survey of TRIKAFTA. The information amusement sustainment of the historical improvements successful lung function, respiratory symptoms and sweat chloride, a marker of CFTR function,” said Deepika Polineni, M.D., MPH, Associate Professor of Pediatrics and Cystic Fibrosis Center Director astatine Washington University School of Medicine successful St. Louis, and a co-investigator of the 445-105 survey (Poster #170). “CFTR modulators similar TRIKAFTA person pivotally changed modular of attraction therapy successful CF, and the CF assemblage continues to payment from ongoing postulation and valuation of semipermanent data.”
Vertex volition besides contiguous information for the archetypal clip from its investigational Phase 3 open-label survey designed to measure the safety, pharmacokinetics and efficacy of TRIKAFTA successful children 2 done 5 years of property with CF and astatine slightest 1 F508del allele (Poster #693). The survey shows that attraction with TRIKAFTA led to improvements successful sweat chloride attraction and lung function, arsenic measured by the lung clearance index, and unchangeable nutritional presumption successful children 2 done 5 years of age. TRIKAFTA was mostly good tolerated, with a information illustration mostly accordant with older property groups. Based connected these results, Vertex precocious submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration for this property scope and volition beryllium filing for approvals with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) by the extremity of this year.
Additionally, Vertex volition contiguous information from a pooled investigation from aggregate Phase 3 studies with CFTR modulators evaluating however the restoration of CFTR-mediated chloride transport, arsenic reflected by changes successful sweat chloride concentration, impacts objective outcomes successful radical with CF treated with CFTR modulators (Poster #694). The survey showed that radical with CF ages 12 years and older treated with CFTR modulators achieved higher levels of CFTR activity, arsenic reflected successful little levels of sweat chloride. Those with greater improvements successful sweat chloride demonstrated greater improvements successful lung function, respiratory symptoms, assemblage wide index, pulmonary exacerbations, and had amended lung relation trajectory implicit time. These caller information show that higher levels of CFTR relation arsenic measured by a simplification of sweat chloride are associated with improved objective outcomes. The champion outcomes were seen successful those achieving a sweat chloride attraction <60 mmol/L.
In addition, Vertex volition contiguous findings from the archetypal afloat decentralized survey successful radical with CF designed to research the feasibility of wearable exertion successful evaluating objective outcomes specified arsenic cough number and carnal enactment (Poster #169 and Oral Workshop: W30.1).
Vertex volition besides contiguous interim results from Phase 3 open-label hold studies evaluating the semipermanent information and efficacy of TRIKAFTA successful children with CF ages 6 years and older (Poster #163 and Thematic Poster: TPS01.2) and radical with CF 12 years and older with F508del-gating oregon F508del-residual relation genotypes (Poster #185 and Thematic Poster: TPS01.5).
“These caller information adhd to the increasing assemblage of grounds demonstrating the benefits of our CFTR modulators crossed aggregate objective measures implicit the long-term, and the important interaction these medicines are having connected patients,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex.
About Cystic Fibrosis
Cystic fibrosis (CF) is simply a rare, life-shortening familial illness affecting much than 83,000 radical globally. CF is simply a progressive, multi-organ illness that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR macromolecule resulting from definite mutations successful the CFTR gene. Children indispensable inherit 2 defective CFTR genes — 1 from each genitor — to person CF, and these mutations tin beryllium identified by a familial test. While determination are galore antithetic types of CFTR mutations that tin origin the disease, the immense bulk of radical with CF person astatine slightest 1 F508del mutation. CFTR mutations pb to CF by causing CFTR macromolecule to beryllium defective oregon by starring to a shortage oregon lack of CFTR macromolecule astatine the compartment surface. The defective relation and/or lack of CFTR macromolecule results successful mediocre travel of brackish and h2o into and retired of the cells successful a fig of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung harm that yet leads to decease for galore patients. The median property of decease is successful the aboriginal 30s.
About TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
U.S. INDICATION AND IMPORTANT SAFETY INFORMATION FOR TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) TABLETS
TRIKAFTA is simply a medicine medicine utilized for the attraction of cystic fibrosis (CF) successful patients aged 6 years and older who person astatine slightest 1 transcript of the F508del mutation successful the cystic fibrosis transmembrane conductance regulator (CFTR) cistron oregon different mutation that is responsive to attraction with TRIKAFTA. Patients should speech to their doc to larn if they person an indicated CF cistron mutation. It is not known if TRIKAFTA is harmless and effectual successful children nether 6 years of age.
Patients should not instrumentality TRIKAFTA if they instrumentality definite medicines oregon herbal supplements, specified as: antibiotics specified arsenic rifampin oregon rifabutin; seizure medicines specified arsenic phenobarbital, carbamazepine, oregon phenytoin; St. John’s wort.
Before taking TRIKAFTA, patients should archer their doc astir each of their aesculapian conditions, including if they: have kidney problems, have oregon person had liver problems, are large oregon program to go large due to the fact that it is not known if TRIKAFTA volition harm an unborn baby, oregon are breastfeeding oregon readying to breastfeed due to the fact that it is not known if TRIKAFTA passes into bosom milk.
TRIKAFTA whitethorn impact the mode different medicines work, and different medicines whitethorn impact however TRIKAFTA works. Therefore, the dose of TRIKAFTA whitethorn request to beryllium adjusted erstwhile taken with definite medicines. Patients should particularly archer their doc if they take: antifungal medicines including ketoconazole, itraconazole, posaconazole, voriconazole, oregon fluconazole; antibiotics including telithromycin, clarithromycin, oregon erythromycin.
TRIKAFTA whitethorn origin dizziness successful immoderate radical who instrumentality it. Patients should not thrust a car, run machinery, oregon bash thing that requires alertness until they cognize however TRIKAFTA affects them.
Patients should debar food oregon portion that contains grapefruit portion they are taking TRIKAFTA.
TRIKAFTA tin origin superior broadside effects, including:
Liver harm and worsening of liver relation in radical with terrible liver illness that tin beryllium superior and whitethorn necessitate transplantation. Liver harm has besides happened successful radical without liver disease.
High liver enzymes successful the blood, which is simply a communal broadside effect successful radical treated with TRIKAFTA. These tin beryllium superior and whitethorn beryllium a motion of liver injury. The patient’s doc volition bash humor tests to cheque their liver earlier they commencement TRIKAFTA, each 3 months during the archetypal twelvemonth of taking TRIKAFTA, and each twelvemonth portion taking TRIKAFTA. Patients should telephone their doc close distant if they person immoderate of the pursuing symptoms of liver problems: symptom oregon discomfort successful the precocious close tummy (abdominal) area; yellowing of the tegument oregon the achromatic portion of the eyes; nonaccomplishment of appetite; nausea oregon vomiting; dark, amber-colored urine.
Abnormality of the oculus lens (cataract) has been noted successful immoderate children and adolescents treated with TRIKAFTA. If the diligent is simply a kid oregon adolescent, their doc should execute oculus examinations earlier and during attraction with TRIKAFTA to look for cataracts.
The astir communal broadside effects of TRIKAFTA include headache, diarrhea, precocious respiratory tract corruption (common cold) including stuffy and runny nose, tummy (abdominal) pain, inflamed sinuses, summation successful liver enzymes, summation successful a definite humor enzyme called creatine phosphokinase, rash, flu (influenza), and summation successful humor bilirubin.
These are not each the imaginable broadside effects of TRIKAFTA.
Please click here to spot the afloat U.S. Prescribing Information for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor).
About Vertex
Vertex is simply a planetary biotechnology institution that invests successful technological innovation to make transformative medicines for radical with superior diseases. The institution has aggregate approved medicines that dainty the underlying origin of cystic fibrosis (CF) — a rare, life-threatening familial illness — and has respective ongoing objective and probe programs successful CF. Beyond CF, Vertex has a robust pipeline of investigational tiny molecule, compartment and familial therapies successful different superior diseases wherever it has heavy penetration into causal quality biology, including sickle compartment disease, beta thalassemia, APOL1-mediated kidney disease, pain, benignant 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
Founded successful 1989 successful Cambridge, Mass., Vertex's planetary office is present located successful Boston's Innovation District and its planetary office is successful London. Additionally, the institution has probe and improvement sites and commercialized offices successful North America, Europe, Australia and Latin America. Vertex is consistently recognized arsenic 1 of the industry's apical places to work, including 13 consecutive years connected Science magazine's Top Employers database and 1 of Fortune’s Best Workplaces successful Biotechnology and Pharmaceuticals and Best Workplaces for Women. For institution updates and to larn much astir Vertex's past of innovation, sojourn www.vrtx.com oregon travel america connected Facebook, Twitter, LinkedIn, YouTube and Instagram.
Special Note Regarding Forward-Looking Statements
This property merchandise contains forward-looking statements arsenic defined successful the Private Securities Litigation Reform Act of 1995, arsenic amended, including, without limitation, statements by Dr. Carmen Bozic and Dr. Deepika Polineni successful this property release, statements regarding the imaginable benefits, information and efficacy of TRIKAFTA, our plans to contiguous information astir our portfolio of CF medicines astatine the NACFC, including information from our TRIKAFTA Phase 3 open-label studies and information from a pooled investigation from aggregate Phase 3 studies with CFTR modulators, and further technological presentations regarding TRIKAFTA, including semipermanent information and efficacy data, expectations to contiguous findings from a survey designed to research wearable exertion successful evaluating objective outcomes, and expectations to record regulatory approvals with the EMA and MHRA by the extremity of this year. While Vertex believes the forward-looking statements contained successful this property merchandise are accurate, these forward-looking statements correspond the company's beliefs lone arsenic of the day of this property merchandise and determination are a fig of risks and uncertainties that could origin existent events oregon results to disagree materially from those expressed oregon implied by specified forward-looking statements. Those risks and uncertainties include, among different things, that information from a constricted fig of patients whitethorn not beryllium indicative of last objective proceedings results, that the institution whitethorn not beryllium capable to taxable the anticipated regulatory filings connected the expected timeline, oregon astatine all, that information from the company's probe and improvement programs whitethorn not enactment registration oregon further improvement of its compounds owed to safety, efficacy, and different risks listed nether the heading “Risk Factors” successful Vertex's astir caller yearly study and consequent quarterly reports filed with the Securities and Exchange Commission astatine www.sec.gov and disposable done the company's website astatine www.vrtx.com. You should not spot undue reliance connected these statements, oregon the technological information presented. Vertex disclaims immoderate work to update the accusation contained successful this property merchandise arsenic caller accusation becomes available.
(VRTX-GEN)
English (US)